WallStSmart

Merck & Company Inc (MRK)vsTandem Diabetes Care Inc (TNDM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 6292% more annual revenue ($66.57B vs $1.04B). MRK leads profitability with a 4.8% profit margin vs -6.1%. MRK earns a higher WallStSmart Score of 34/100 (F).

MRK

Avoid

34

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

TNDM

Avoid

28

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -0.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-84.6%)

Margin of Safety

-84.6%

Fair Value

$82.62

Current Price

$148.35

$65.73 premium

UndervaluedFair: $82.62Overvalued

Intrinsic value data unavailable for TNDM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$335.46B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

TNDM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.7x4/10

Trading at 8.7x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

TNDM4 concerns · Avg: 3.0/10
Price/BookValuation
11.4x4/10

Trading at 11.4x book value

Market CapQuality
$1.49B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-71.4%2/10

ROE of -71.4% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : TNDM

TNDM has a balanced fundamental profile.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 108.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : TNDM

The primary concerns for TNDM are Price/Book, Market Cap, Piotroski F-Score. Debt-to-equity of 5.67 is elevated, increasing financial risk.

Key Dynamics to Monitor

MRK profiles as a value stock while TNDM is a turnaround play — different risk/reward profiles.

TNDM carries more volatility with a beta of 1.54 — expect wider price swings.

TNDM is growing revenue faster at 5.8% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (34/100 vs 28/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Tandem Diabetes Care Inc

HEALTHCARE · MEDICAL DEVICES · USA

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and markets various products for people with insulin-dependent diabetes in the United States. The company is headquartered in San Diego, California.

Visit Website →

Want to dig deeper into these stocks?